Topical Drug Delivery Market by Product (Formulation (Semi-solid, Emulsion), Transdermal Patch, Microneedle Patch, Drug-in-adhesive, Matrix Patch), Application (Dermal, Ophthalmic, Nasal, Vaginal, Rectal), End User, Region - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.2.2 MARKETS & REGIONS COVERED
  • 1.2.3 YEARS CONSIDERED
  • 1.2.4 CURRENCY CONSIDERED
• 1.3 MARKET STAKEHOLDERS
• 1.4 LIMITATIONS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH METHODOLOGY DESIGN
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Key data from primary sources
    • 2.2.2.2 Key industry insights
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 APPROACH 1: REVENUE SHARE ANALYSIS
  • 2.3.2 APPROACH 2: PHARMACEUTICAL SALES ANALYSIS
  • 2.3.3 APPROACH 3: TOP-DOWN APPROACH
  • 2.3.4 APPROACH 4: BOTTOM-UP APPROACH
  • 2.3.5 APPROACH 4: PRIMARY INTERVIEWS
  • 2.3.6 APPROACH 5: DEMAND-SIDE APPROACH
  • 2.3.7 APPROACH 6: VOLUME DATA ANALYSIS
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ANALYSIS
• 2.6 STUDY ASSUMPTIONS
  • 2.6.1 GROWTH RATE ASSUMPTIONS
• 2.7 RISK ASSESSMENT
• 2.8 LIMITATIONS
  • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
• 4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT & COUNTRY (2024)
• 4.3 TOPICAL DRUG DELIVERY MARKET: REGIONAL MIX
• 4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of skin disorders
    • 5.2.1.2 High incidence of burn injuries
    • 5.2.1.3 Growing emphasis on patient convenience
    • 5.2.1.4 Increasing investments in pharmaceutical R&D
    • 5.2.1.5 Rising incidence of chronic diseases
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Adverse skin reactions & allergies
    • 5.2.2.2 Drug failure & recalls of TDD systems
    • 5.2.2.3 High development costs of topical drug delivery products
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for self-administration and home care
    • 5.2.3.2 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Technical barriers related to skin irritation & permeability
• 5.3 INDUSTRY TRENDS
  • 5.3.1 ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS
  • 5.3.2 EMERGENCE OF MICRONEEDLE PATCH TECHNOLOGIES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Nanocarrier-based delivery systems
    • 5.4.1.2 Microemulsions & nanoemulsion
    • 5.4.1.3 Thermosensitive & pH-sensitive hydrogels & hydrocolloids
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Microneedle-enhanced delivery
    • 5.4.2.2 AI-assisted formulations & prediction models
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Wearable sensor-integrated topical patches
    • 5.4.3.2 3D testing skin models
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 THREAT OF SUBSTITUTES
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
  • 5.5.4 BARGAINING POWER OF BUYERS
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
  • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
  • 5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 TRADE DATA FOR HS CODE 300490
    • 5.8.1.1 Import data for HS Code 300490
    • 5.8.1.2 Export data for HS Code 300490
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022-2024
  • 5.9.2 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
  • 5.9.3 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
  • 5.9.4 AVERAGE SELLING PRICE, BY REGION
  • 5.9.5 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
    • 5.9.5.1 Average selling price trend of ointments, by region, 2022-2024
    • 5.9.5.2 Average selling price trend of creams, by region, 2022-2024
    • 5.9.5.3 Average selling price trend of gels, by region, 2022-2024
• 5.10 REIMBURSEMENT ANALYSIS
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 UNMET NEEDS/END-USER EXPECTATIONS
• 5.14 IMPACT OF AI ON TOPICAL DRUG DELIVERY MARKET
  • 5.14.1 AI-USE CASES
• 5.15 PIPELINE ANALYSIS
• 5.16 ECOSYSTEM MARKET MAP
• 5.17 VALUE CHAIN ANALYSIS
• 5.18 INVESTMENT & FUNDING SCENARIO
• 5.19 TRUMP TARIFF IMPACT ON TOPICAL DRUG DELIVERY MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
  • 5.19.4 KEY IMPACT ON VARIOUS REGIONS
  • 5.19.5 END-USE INDUSTRY IMPACT

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 SEMI-SOLID FORMULATIONS
  • 6.2.1 OINTMENTS
    • 6.2.1.1 Wide applications in analgesic indications to drive market
  • 6.2.2 CREAMS
    • 6.2.2.1 High absorption capabilities to boost demand
  • 6.2.3 LOTIONS
    • 6.2.3.1 Convenient application to fuel uptake
  • 6.2.4 GELS
    • 6.2.4.1 Enhanced patient compliance and aesthetic appeal to drive market
  • 6.2.5 PASTES
    • 6.2.5.1 Prevention of skin irritation to fuel uptake
• 6.3 LIQUID FORMULATIONS
  • 6.3.1 SUSPENSIONS
    • 6.3.1.1 Higher rate of bioavailability and controlled onset of action to drive market
  • 6.3.2 EMULSIONS
    • 6.3.2.1 Versatile carriers for enhanced drug delivery to fuel uptake
  • 6.3.3 SOLUTIONS
    • 6.3.3.1 Uniform & rapid drug delivery to boost demand
• 6.4 SOLID FORMULATIONS
  • 6.4.1 POWDERS
    • 6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel market
  • 6.4.2 SUPPOSITORIES
    • 6.4.2.1 Ability to ensure drug compatibility to fuel market
  • 6.4.3 FILM
    • 6.4.3.1 Next-generation advancements to boost demand
• 6.5 TRANSDERMAL PRODUCTS
  • 6.5.1 TRANSDERMAL PATCHES
    • 6.5.1.1 Drug-in-adhesive patches
      • 6.5.1.1.1 Enhanced drug release to fuel uptake
    • 6.5.1.2 Matrix patches
      • 6.5.1.2.1 Rising technological advancements to boost demand
    • 6.5.1.3 Reservoir membrane patches
      • 6.5.1.3.1 Prolonged drug delivery to fuel market
    • 6.5.1.4 Microneedle patches
      • 6.5.1.4.1 Ability to deliver APIs to support market growth
    • 6.5.1.5 Iontophoresis patches
      • 6.5.1.5.1 Low molecular weight patches to support market growth
    • 6.5.1.6 Vapor patches
      • 6.5.1.6.1 Ability to release essential oils to support market growth
  • 6.5.2 TRANSDERMAL GELS
    • 6.5.2.1 Rapid release of drugs to fuel uptake
  • 6.5.3 TRANSDERMAL SPRAYS
    • 6.5.3.1 Targeted approach to boost demand
• 6.6 OTHER PRODUCTS

7 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION

• 7.1 INTRODUCTION
• 7.2 DERMAL DRUG DELIVERY
  • 7.2.1 STANDARD MEDIUM WITH HIGH DRUG ABSORPTION TO PROPEL MARKET
• 7.3 OPHTHALMIC DRUG DELIVERY
  • 7.3.1 FOCUS ON MICROEMULSION-BASED FORMULATIONS TO BOOST DEMAND
• 7.4 VAGINAL DRUG DELIVERY
  • 7.4.1 LIMITED INTERVENTION BY MEDICAL PERSONNEL TO DRIVE MARKET
• 7.5 RECTAL DRUG DELIVERY
  • 7.5.1 COMBINATION OF LOCAL & SYSTEMIC THERAPY OF DRUGS TO FUEL UPTAKE
• 7.6 NASAL DRUG DELIVERY
  • 7.6.1 QUICK ONSET OF DRUG ACTION & CONVENIENCE TO SUPPORT MARKET UPTAKE

8 TOPICAL DRUG DELIVERY MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOME CARE SETTINGS
  • 8.2.1 HIGH PREFERENCE, AFFORDABILITY, AND CONVENIENCE TO PROPEL MARKET
• 8.3 HOSPITALS & CLINICS
  • 8.3.1 ADOPTION OF TOPICAL ANAESTHETICS FOR MEDICAL & SURGICAL SUB-SPECIALTIES TO DRIVE MARKET
• 8.4 AMBULATORY SURGERY CENTERS
  • 8.4.1 UTILIZATION OF ANTIMICROBIAL TOPICAL DRUGS FOR TRAUMA CASES TO BOOST DEMAND
• 8.5 BURN CARE CENTERS
  • 8.5.1 HIGH INCIDENCE OF BURN INJURIES AND UPTAKE OF OINTMENTS TO SUPPORT MARKET GROWTH
• 8.6 OTHER END USERS

9 TOPICAL DRUG DELIVERY MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Rising prevalence of skin diseases to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Growing focus of R&D for pharmaceutical API development to boost demand
  • 9.3.3 UK
    • 9.3.3.1 Rising demand for painless treatment alternatives to fuel market
  • 9.3.4 FRANCE
    • 9.3.4.1 Rising incidence of diabetes and subsequent increase in skin lesions to drive market
  • 9.3.5 ITALY
    • 9.3.5.1 Rising demand for transdermal patches to propel market
  • 9.3.6 SPAIN
    • 9.3.6.1 Expanding research hub to fuel market
  • 9.3.7 NETHERLANDS
    • 9.3.7.1 Public awareness initiatives for preventive care to fuel uptake
  • 9.3.8 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Rising cases of communicable diseases to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Increasing number of product approvals to drive market
  • 9.4.4 INDIA
    • 9.4.4.1 Growing focus on adoption of non-invasive drug delivery methods to drive market
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increasing number of smokers to fuel uptake
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Favorable government focus on expanding clinical trials to boost demand
  • 9.4.7 THAILAND
    • 9.4.7.1 Regulatory reforms and supportive healthcare initiatives to support market growth
  • 9.4.8 VIETNAM
    • 9.4.8.1 Increasing investments and regulatory reforms to fuel uptake
  • 9.4.9 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 High prevalence of diabetes to propel market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Increasing prevalence of glaucoma to drive market
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 9.6.2.1.1 Expanding healthcare infrastructure to boost demand
    • 9.6.2.2 United Arab Emirates (UAE)
      • 9.6.2.2.1 Increasing prevalence of diabetes to fuel uptake
    • 9.6.2.3 Other GCC Countries
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
• 10.3 REVENUE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS
  • 10.4.1 RANKING OF KEY MARKET PLAYERS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 Site of application footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.6.5.1 Detailed list of key startups/SME players
    • 10.6.5.2 Competitive benchmarking of key emerging players/startups
• 10.7 BRAND/PRODUCT COMPARISON
  • 10.7.1 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• 10.8 R&D EXPENDITURE OF KEY PLAYERS
  • 10.8.1 R&D EXPENDITURE OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
• 10.9 COMPANY VALUATION & FINANCIAL METRICS
  • 10.9.1 FINANCIAL METRICS
  • 10.9.2 COMPANY VALUATION
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
  • 10.10.2 DEALS
  • 10.10.3 EXPANSIONS
  • 10.10.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 JOHNSON & JOHNSON SERVICES, INC.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 GALDERMA
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches & approvals
      • 11.1.2.3.2 Deals
      • 11.1.2.3.3 Expansions
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 BAYER AG
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches & approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 NOVARTIS AG
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Deals
      • 11.1.4.3.2 Other developments
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 ABBVIE INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches
      • 11.1.5.3.2 Expansions
      • 11.1.5.3.3 Other developments
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Key strengths
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 GLENMARK PHARMACEUTICALS LIMITED
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product approvals
      • 11.1.6.3.2 Deals
  • 11.1.7 GSK PLC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Deals
      • 11.1.7.3.2 Other developments
  • 11.1.8 BAUSCH HEALTH COMPANIES INC.
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches & approvals
      • 11.1.8.3.2 Deals
  • 11.1.9 HISAMITSU PHARMACEUTICAL CO., INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product launches, enhancements, and approvals
      • 11.1.9.3.2 Deals
      • 11.1.9.3.3 Expansions
  • 11.1.10 CIPLA
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
  • 11.1.11 VIATRIS INC.
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product launches & approvals
      • 11.1.11.3.2 Deals
      • 11.1.11.3.3 Other developments
  • 11.1.12 ORGANON GROUP OF COMPANIES
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product approvals
      • 11.1.12.3.2 Deals
  • 11.1.13 PFIZER, INC.
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product approvals
      • 11.1.13.3.2 Deals
  • 11.1.14 CRESCITA THERAPEUTICS INC.
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Deals
      • 11.1.14.3.2 Other developments
  • 11.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Deals
      • 11.1.15.3.2 Expansions
  • 11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products offered
    • 11.1.16.3 Recent developments
      • 11.1.16.3.1 Deals
  • 11.1.17 SOLVENTUM
    • 11.1.17.1 Business overview
    • 11.1.17.2 Products offered
    • 11.1.17.3 Recent developments
      • 11.1.17.3.1 Deals
  • 11.1.18 LUYE PHARMA GROUP
    • 11.1.18.1 Business overview
    • 11.1.18.2 Products offered
    • 11.1.18.3 Recent developments
      • 11.1.18.3.1 Product approvals
      • 11.1.18.3.2 Deals
  • 11.1.19 LEAD CHEMICAL CO., LTD.
    • 11.1.19.1 Business overview
    • 11.1.19.2 Products offered
  • 11.1.20 PURDUE PHARMA L.P.
    • 11.1.20.1 Business overview
    • 11.1.20.2 Products offered
  • 11.1.21 LAVIPHARM
    • 11.1.21.1 Business overview
    • 11.1.21.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 CMP PHARMA, INC.
  • 11.2.2 ENCORE DERMATOLOGY, INC.
  • 11.2.3 RUSAN PHARMA LTD.
  • 11.2.4 ADHEXPHARMA

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 RELATED REPORTS
• 12.4 AUTHOR DETAILS

List of Tables

• TABLE 1 STANDARD CURRENCY CONVERSION RATES (USD)
• TABLE 2 TOPICAL DRUG DELIVERY MARKET: RISK ASSESSMENT ANALYSIS
• TABLE 3 KEY DEVELOPMENTS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS
• TABLE 4 TOPICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 5 REGULATORY ADHERENCE FOR TOPICAL DRUG DELIVERY PRODUCTS, BY REGION
• TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 10 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 TOPICAL DRUG DELIVERY MARKET: MAJOR PATENTS
• TABLE 13 IMPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021-2024 (USD THOUSANDS)
• TABLE 14 EXPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021-2024 (USD THOUSANDS)
• TABLE 15 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022-2024
• TABLE 16 AVERAGE SELLING PRICE TREND OF OINTMENTS, BY REGION, 2022-2024
• TABLE 17 AVERAGE SELLING PRICE TREND FOR CREAMS, BY REGION, 2022-2024
• TABLE 18 AVERAGE SELLING PRICE TREND OF GELS, BY REGION, 2022-2024
• TABLE 19 TOPICAL DRUG DELIVERY MARKET: KEY CONFERENCES & EVENTS, 2025-2026
• TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS (%)
• TABLE 21 KEY BUYING CRITERIA, BY END USER
• TABLE 22 TOPICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE (2024)
• TABLE 23 TOPICAL DRUG DELIVERY PRODUCTS PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 25 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR TOPICAL DRUG DELIVERY PRODUCTS
• TABLE 26 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
• TABLE 27 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
• TABLE 28 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
• TABLE 29 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
• TABLE 30 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 31 KEY PLAYERS OFFERING SEMI-SOLID FORMULATIONS
• TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 33 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 34 KEY PLAYERS OFFERING OINTMENTS
• TABLE 35 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
• TABLE 36 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 37 KEY PLAYERS OFFERING CREAMS
• TABLE 38 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
• TABLE 39 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 40 KEY PLAYERS OFFERING LOTIONS
• TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 42 KEY PLAYERS OFFERING GELS
• TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
• TABLE 44 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 45 KEY PLAYERS OFFERING PASTES
• TABLE 46 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
• TABLE 47 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 48 KEY PLAYERS OFFERING LIQUID FORMULATIONS
• TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 50 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 51 KEY PLAYERS OFFERING SUSPENSIONS
• TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 53 KEY PLAYERS OFFERING EMULSIONS
• TABLE 54 TOPICAL DRUG DELIVERY MARKET FOR EMULSIONS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 55 KEY PLAYERS OFFERING SOLUTIONS
• TABLE 56 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 57 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 58 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 59 KEY PLAYERS OFFERING SOLID FORMULATIONS
• TABLE 60 KEY PLAYERS OFFERING POWDERS
• TABLE 61 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 62 KEY PLAYERS OFFERING SUPPOSITORIES
• TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 64 KEY PLAYERS OFFERING FILM
• TABLE 65 TOPICAL DRUG DELIVERY MARKET FOR FILM, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 66 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 67 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 68 KEY PLAYERS OFFERING TRANSDERMAL PRODUCTS
• TABLE 69 KEY PLAYERS OFFERING TRANSDERMAL PATCHES
• TABLE 70 TRANSDERMAL PATCHES MARKET, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 71 TRANSDERMAL PATCHES MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
• TABLE 72 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 73 KEY PLAYERS OFFERING DRUG-IN-ADHESIVE PATCHES
• TABLE 74 TRANSDERMAL DRUG-IN-ADHESIVE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 75 KEY PLAYERS OFFERING MATRIX PATCHES
• TABLE 76 TRANSDERMAL MATRIX PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 77 KEY PLAYERS OFFERING RESERVOIR MEMBRANE PATCHES
• TABLE 78 TRANSDERMAL RESERVOIR MEMBRANE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 79 KEY PLAYERS OFFERING MICRONEEDLE PATCHES
• TABLE 80 TRANSDERMAL MICRONEEDLE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 81 KEY PLAYERS OFFERING IONTOPHORESIS PATCHES
• TABLE 82 TRANSDERMAL IONTOPHORESIS PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 83 KEY PLAYERS OFFERING VAPOR PATCHES
• TABLE 84 TRANSDERMAL VAPOR PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 85 KEY PLAYERS OFFERING TRANSDERMAL GELS
• TABLE 86 TRANSDERMAL GELS MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
• TABLE 87 TRANSDERMAL GELS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 88 KEY PLAYERS OFFERING TRANSDERMAL SPRAYS
• TABLE 89 TRANSDERMAL SPRAYS MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
• TABLE 90 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 91 TOPICAL DRUG DELIVERY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 92 KEY PLAYERS OFFERING OTHER PRODUCTS
• TABLE 93 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 94 KEY PLAYERS OFFERING DERMAL DRUG DELIVERY PRODUCTS
• TABLE 95 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 96 KEY PLAYERS OFFERING OPHTHALMIC DRUG DELIVERY PRODUCTS
• TABLE 97 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 98 KEY PLAYERS OFFERING VAGINAL DRUG DELIVERY PRODUCTS
• TABLE 99 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 100 KEY PLAYERS OFFERING RECTAL DRUG DELIVERY PRODUCTS
• TABLE 101 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 102 KEY PLAYERS OFFERING NASAL DRUG DELIVERY PRODUCTS
• TABLE 103 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 104 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 105 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 106 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 107 TOPICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 108 TOPICAL DRUG DELIVERY MARKET FOR BURN CARE CENTERS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 109 TOPICAL DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 110 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
• TABLE 111 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 112 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 113 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 114 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 115 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 116 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 117 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 118 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 119 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 120 US: KEY MACROINDICATORS
• TABLE 121 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 122 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 123 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 124 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 125 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 126 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 127 US: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 128 US: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 129 CANADA: KEY MACROINDICATORS
• TABLE 130 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 131 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 132 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 133 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 134 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 135 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 136 CANADA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 137 CANADA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 138 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 139 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 140 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 141 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 142 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 143 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 144 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 145 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 146 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 147 GERMANY: KEY MACROINDICATORS
• TABLE 148 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 149 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 150 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 151 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 152 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 153 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 154 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 155 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 156 UK: KEY MACROINDICATORS
• TABLE 157 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 158 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 159 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 160 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 161 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 162 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 163 UK: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 164 UK: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 165 FRANCE: KEY MACROINDICATORS
• TABLE 166 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 167 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 168 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 169 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 170 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 171 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 172 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 173 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 174 ITALY: KEY MACROINDICATORS
• TABLE 175 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 176 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 177 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 178 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 179 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 180 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 181 ITALY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 182 ITALY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 183 SPAIN: KEY MACROINDICATORS
• TABLE 184 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 185 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 186 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 187 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 188 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 189 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 190 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 191 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 192 NETHERLANDS: KEY MACROINDICATORS
• TABLE 193 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 194 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 195 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 196 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 197 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 198 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 199 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 200 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 201 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 202 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 203 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 204 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 205 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 206 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 207 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 208 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 209 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 210 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 211 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 212 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 213 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 214 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 215 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 216 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 217 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 218 CHINA: MACROECONOMIC INDICATORS
• TABLE 219 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 220 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 221 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 222 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 223 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 224 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 225 CHINA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 226 CHINA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 227 JAPAN: MACROECONOMIC INDICATORS
• TABLE 228 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 229 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 230 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 231 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 232 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 233 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 234 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 235 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 236 INDIA: MACROECONOMIC INDICATORS
• TABLE 237 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 238 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 239 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 240 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 241 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 242 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 243 INDIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 244 INDIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 245 AUSTRALIA: KEY MACROINDICATORS
• TABLE 246 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 247 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 248 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 249 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 250 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 251 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 252 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 253 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 254 SOUTH KOREA: MACROECONOMIC INDICATORS
• TABLE 255 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 256 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 257 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 258 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 259 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 260 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 261 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 262 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 263 THAILAND: MACROECONOMIC INDICATORS
• TABLE 264 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 265 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 266 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 267 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 268 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 269 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 270 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 271 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 272 VIETNAM: MACROECONOMIC INDICATORS
• TABLE 273 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 274 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 275 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 276 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 277 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 278 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 279 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 280 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 281 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 282 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 283 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 284 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 285 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 286 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 287 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 288 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 289 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 290 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 291 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 292 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 293 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 294 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 295 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 296 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 297 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 298 BRAZIL: MACROECONOMIC INDICATORS
• TABLE 299 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 300 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 301 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 302 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 303 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 304 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 305 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 306 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 307 MEXICO: MACROECONOMIC INDICATORS
• TABLE 308 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 309 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 310 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 311 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 312 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 313 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 314 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 315 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 316 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 317 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 318 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 319 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 320 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 321 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 322 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 323 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 324 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
• TABLE 325 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 326 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 327 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 328 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 329 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 330 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 331 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 332 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 333 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
• TABLE 334 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 335 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 336 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 337 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 338 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 339 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 340 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 341 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 342 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
• TABLE 343 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 344 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 345 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 346 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 347 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 348 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 349 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 350 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 351 UNITED ARAB EMIRATES: KEY MACROINDICATORS
• TABLE 352 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 353 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 354 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 355 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 356 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 357 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 358 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 359 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 360 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 361 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 362 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 363 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 364 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 365 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 366 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 367 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 368 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
• TABLE 369 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 370 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 371 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 372 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 373 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
• TABLE 374 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
• TABLE 375 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
• TABLE 376 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
• TABLE 377 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
• TABLE 378 TOPICAL DRUG DELIVERY MARKET: REGION FOOTPRINT
• TABLE 379 TOPICAL DRUG DELIVERY MARKET: PRODUCT TYPE FOOTPRINT
• TABLE 380 TOPICAL DRUG DELIVERY MARKET: SITE OF APPLICATION FOOTPRINT
• TABLE 381 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
• TABLE 382 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 383 TOPICAL DRUG DELIVERY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 384 TOPICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2022-JUNE 2025
• TABLE 385 TOPICAL DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 386 TOPICAL DRUG DELIVERY MARKET: OTHERS, JANUARY 2022-JUNE 2025
• TABLE 387 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
• TABLE 388 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
• TABLE 389 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 390 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 391 GALDERMA: COMPANY OVERVIEW
• TABLE 392 GALDERMA: PRODUCTS OFFERED
• TABLE 393 GALDERMA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 394 GALDERMA: DEALS, JANUARY 2022-JUNE 2025
• TABLE 395 GALDERMA: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 396 BAYER AG: COMPANY OVERVIEW
• TABLE 397 BAYER AG: PRODUCTS OFFERED
• TABLE 398 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 399 BAYER AG: DEALS, JANUARY 2022-JUNE 2025
• TABLE 400 NOVARTIS AG: COMPANY OVERVIEW
• TABLE 401 NOVARTIS AG: PRODUCTS OFFERED
• TABLE 402 NOVARTIS AG: DEALS, JANUARY 2022-JUNE 2025
• TABLE 403 NOVARTIS AG: OTHERS, JANUARY 2022-JUNE 2025
• TABLE 404 ABBVIE INC.: COMPANY OVERVIEW
• TABLE 405 ABBVIE, INC.: PRODUCTS OFFERED
• TABLE 406 ABBVIE INC.: PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025
• TABLE 407 ABBVIE, INC.: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 408 ABBVIE INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
• TABLE 409 GLENMARK PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
• TABLE 410 GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
• TABLE 411 GLENMARK PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 412 GLENMARK PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022-JUNE 2025
• TABLE 413 GSK PLC.: COMPANY OVERVIEW
• TABLE 414 GSK PLC.: PRODUCTS OFFERED
• TABLE 415 GSK PLC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 416 GSK PLC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
• TABLE 417 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW
• TABLE 418 BAUSCH HEALTH COMPANIES, INC.: PRODUCTS OFFERED
• TABLE 419 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 420 BAUSCH HEALTH COMPANIES INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 421 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY OVERVIEW
• TABLE 422 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCTS OFFERED
• TABLE 423 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 424 HISAMITSU PHARMACEUTICAL CO., INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 425 HISAMITSU PHARMACEUTICAL CO., INC.: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 426 CIPLA: COMPANY OVERVIEW
• TABLE 427 CIPLA: PRODUCTS OFFERED
• TABLE 428 CIPLA: DEALS, JANUARY 2022-JUNE 2025
• TABLE 429 VIATRIS INC.: COMPANY OVERVIEW
• TABLE 430 VIATRIS INC.: PRODUCTS OFFERED
• TABLE 431 VIATRIS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 432 VIATRIS INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 433 VIATRIS INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
• TABLE 434 ORGANON GROUP OF COMPANIES: COMPANY OVERVIEW
• TABLE 435 ORGANON GROUP OF COMPANIES: PRODUCTS OFFERED
• TABLE 436 ORGANON GROUP OF COMPANIES: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 437 ORGANON GROUP OF COMPANIES: DEALS, JANUARY 2022-JUNE 2025
• TABLE 438 PFIZER INC.: COMPANY OVERVIEW
• TABLE 439 PFIZER INC.: PRODUCTS OFFERED
• TABLE 440 PFIZER, INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 441 PFIZER, INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 442 CRESCITA THERAPEUTICS INC.: COMPANY OVERVIEW
• TABLE 443 CRESCITA THERAPEUTICS INC.: PRODUCTS OFFERED
• TABLE 444 CRESCITA THERAPEUTICS INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 445 CRESCITA THERAPEUTICS INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
• TABLE 446 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
• TABLE 447 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
• TABLE 448 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022-JUNE 2025
• TABLE 449 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 450 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
• TABLE 451 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
• TABLE 452 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 453 SOLVENTUM: COMPANY OVERVIEW
• TABLE 454 SOLVENTUM: PRODUCTS OFFERED
• TABLE 455 SOLVENTUM DEALS, JANUARY 2022-JUNE 2025
• TABLE 456 LUYE PHARMA GROUP: COMPANY OVERVIEW
• TABLE 457 LUYE PHARMA GROUP: PRODUCTS OFFERED
• TABLE 458 LUYE PHARMA GROUP: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 459 LUYE PHARMA GROUP: DEALS, JANUARY 2022-JUNE 2025
• TABLE 460 LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW
• TABLE 461 PURDUE PHARMA L.P.: COMPANY OVERVIEW
• TABLE 462 PURDUE PHARMA L.P.: PRODUCTS OFFERED
• TABLE 463 LAVIPHARM: COMPANY OVERVIEW
• TABLE 464 LAVIPHARM: PRODUCTS OFFERED
• TABLE 465 CMP PHARMA, INC.: COMPANY OVERVIEW
• TABLE 466 ENCORE DERMATOLOGY, INC.: COMPANY OVERVIEW
• TABLE 467 RUSAN PHARMA LTD.: COMPANY OVERVIEW
• TABLE 468 ADHEXPHARMA: COMPANY OVERVIEW

List of Figures

• FIGURE 1 TOPICAL DRUG DELIVERY MARKET & REGIONAL SEGMENTATION
• FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH DESIGN
• FIGURE 3 PRIMARY SOURCES
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS
• FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
• FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
• FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
• FIGURE 8 TOPICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
• FIGURE 9 REVENUE ANALYSIS OF TOP FIVE COMPANIES: TOPICAL DRUG DELIVERY MARKET (2024)
• FIGURE 10 PHARMACEUTICAL SALES APPROACH
• FIGURE 11 TOP-DOWN APPROACH
• FIGURE 12 BOTTOM-UP APPROACH
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2025-2030): IMPACT ON MARKET GROWTH & CAGR)
• FIGURE 14 CAGR PROJECTIONS
• FIGURE 15 DATA TRIANGULATION METHODOLOGY
• FIGURE 16 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
• FIGURE 17 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2025 VS. 2030 (USD BILLION)
• FIGURE 18 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
• FIGURE 19 GEOGRAPHIC SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET
• FIGURE 20 INCREASING PREVALENCE OF SKIN DISORDERS AND RISING INCIDENCE OF BURN INJURIES TO PROPEL MARKET
• FIGURE 21 SEMI-SOLID FORMULATIONS SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
• FIGURE 22 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
• FIGURE 23 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
• FIGURE 25 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 26 BIOPHARMACEUTICAL R&D SPENDING (2020-2026)
• FIGURE 27 TOP PHARMA R&D INVESTMENTS: LEADING COMPANY INVESTMENTS, 2023
• FIGURE 28 TOPICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 29 TOPICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2014-JUNE 2025)
• FIGURE 30 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2014-JUNE 2025)
• FIGURE 31 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
• FIGURE 32 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
• FIGURE 33 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
• FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS
• FIGURE 35 KEY BUYING CRITERIA FOR TOPICAL DRUG DELIVERY PRODUCTS, BY TOP THREE END USERS
• FIGURE 36 AI-USE CASES
• FIGURE 37 TOPICAL DRUG DELIVERY MARKET: ECOSYSTEM MAP
• FIGURE 38 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
• FIGURE 39 TOPICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO, 2020-2024
• FIGURE 40 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• FIGURE 41 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
• FIGURE 42 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
• FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2022-2024
• FIGURE 44 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 45 RANKING OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2024
• FIGURE 46 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 47 TOPICAL DRUG DELIVERY MARKET: COMPANY FOOTPRINT
• FIGURE 48 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 49 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 50 R&D EXPENDITURE OF KEY PLAYERS, 2022-2024
• FIGURE 51 EV/EBITDA OF KEY VENDORS
• FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 54 GALDERMA: COMPANY SNAPSHOT (2024)
• FIGURE 55 BAYER AG: COMPANY SNAPSHOT (2024)
• FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT (2024)
• FIGURE 57 ABBVIE, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 58 GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024)
• FIGURE 59 GSK PLC.: COMPANY SNAPSHOT (2024)
• FIGURE 60 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024)
• FIGURE 61 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2024)
• FIGURE 62 CIPLA: COMPANY SNAPSHOT (2024)
• FIGURE 63 VIATRIS INC.: COMPANY SNAPSHOT (2024)
• FIGURE 64 ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024)
• FIGURE 65 PFIZER, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 66 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2024)
• FIGURE 67 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
• FIGURE 68 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
• FIGURE 69 SOLVENTUM: COMPANY SNAPSHOT (2024)
• FIGURE 70 LUYE PHARMA GROUP: COMPANY SNAPSHOT (2023)
• FIGURE 71 COMPANY SNAPSHOT: LAVIPHARM (2024)